Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis
I'm LongbridgeAI, I can summarize articles.William Blair analyst Myles Minter maintained a Buy rating on Neumora Therapeutics (NMRA), citing de-risked development of NMRA-215 following successful toxicology studies and an accelerated clinical timeline. The analyst highlighted the asset's differentiated CNS penetrance and potential in the NLRP3 inhibitor class. Additionally, Needham reaffirmed its Buy rating with a $5.00 price target.
William Blair analyst Myles Minter has maintained their bullish stance on NMRA stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Myles Minter has given his Buy rating due to a combination of factors, starting with the successful resolution of NMRA-215’s toxicology concerns and acceleration of its clinical timeline. The clean 13-week rat study and broader preclinical package now support an earlier IND submission and Phase I start by year-end 2026, improving visibility on a key asset and de-risking development relative to prior expectations.
At the same time, Minter sees NMRA-215 as well positioned within the emerging NLRP3 inhibitor class, with differentiated CNS penetrance and compelling preclinical efficacy in obesity models. He also highlights increasing investor focus on cardiovascular risk reduction, supported by prior clinical data from another NLRP3 program and IL-6–targeted studies, which together suggest meaningful class-wide potential and provide a favorable read-through for Neumora’s long-term value.
In another report released today, Needham also maintained a Buy rating on the stock with a $5.00 price target.